GB0105131D0 - Compositions having improved bioavailability - Google Patents

Compositions having improved bioavailability

Info

Publication number
GB0105131D0
GB0105131D0 GBGB0105131.7A GB0105131A GB0105131D0 GB 0105131 D0 GB0105131 D0 GB 0105131D0 GB 0105131 A GB0105131 A GB 0105131A GB 0105131 D0 GB0105131 D0 GB 0105131D0
Authority
GB
United Kingdom
Prior art keywords
compositions
improved bioavailability
bioavailability
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0105131.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB0105131.7A priority Critical patent/GB0105131D0/en
Publication of GB0105131D0 publication Critical patent/GB0105131D0/en
Priority to US10/075,800 priority patent/US6579898B2/en
Priority to MXPA03007836A priority patent/MXPA03007836A/en
Priority to EP02712162A priority patent/EP1372785A2/en
Priority to PCT/IB2002/000512 priority patent/WO2002070070A2/en
Priority to JP2002569239A priority patent/JP2004529893A/en
Priority to CA002439917A priority patent/CA2439917A1/en
Priority to BR0207751-5A priority patent/BR0207751A/en
Priority to AU2002232061A priority patent/AU2002232061A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
GBGB0105131.7A 2001-03-01 2001-03-01 Compositions having improved bioavailability Ceased GB0105131D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0105131.7A GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability
US10/075,800 US6579898B2 (en) 2001-03-01 2002-02-13 Compositions having improved bioavailability
MXPA03007836A MXPA03007836A (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability.
EP02712162A EP1372785A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan
PCT/IB2002/000512 WO2002070070A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan
JP2002569239A JP2004529893A (en) 2001-03-01 2002-02-20 Compositions with improved bioavailability
CA002439917A CA2439917A1 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan
BR0207751-5A BR0207751A (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability
AU2002232061A AU2002232061A1 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0105131.7A GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability

Publications (1)

Publication Number Publication Date
GB0105131D0 true GB0105131D0 (en) 2001-04-18

Family

ID=9909814

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0105131.7A Ceased GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability

Country Status (8)

Country Link
EP (1) EP1372785A2 (en)
JP (1) JP2004529893A (en)
AU (1) AU2002232061A1 (en)
BR (1) BR0207751A (en)
CA (1) CA2439917A1 (en)
GB (1) GB0105131D0 (en)
MX (1) MXPA03007836A (en)
WO (1) WO2002070070A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010070A (en) * 2003-04-11 2005-11-23 Pfizer Pharmaceutical combination comprising eletriptan and sodium bicarbonate.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709739D0 (en) * 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine

Also Published As

Publication number Publication date
JP2004529893A (en) 2004-09-30
WO2002070070A3 (en) 2003-04-10
EP1372785A2 (en) 2004-01-02
MXPA03007836A (en) 2003-12-08
BR0207751A (en) 2004-03-09
CA2439917A1 (en) 2002-09-12
WO2002070070A2 (en) 2002-09-12
AU2002232061A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
GB0127143D0 (en) Novel compounds
AU2002359165A8 (en) Novel compounds
HUP0400174A2 (en) Lipid-polymer-conjugates compositions
GB0129489D0 (en) Sustained-release compositions
GB0200763D0 (en) Compositions
EG23126A (en) Novel fungicial compositions
HUP0600303A2 (en) Pentafluorpropane based compositions
GB0105622D0 (en) Compositions
GB0114532D0 (en) Novel compositions
GB0104259D0 (en) Novel compounds
GB0105131D0 (en) Compositions having improved bioavailability
GB0103328D0 (en) Compositions
GB0102470D0 (en) Novel compounds
GB0102713D0 (en) Novel compounds
HK1033137A1 (en) Imidosilane compositions
GB0101392D0 (en) Compositions
GB0112345D0 (en) Compositions
GB0101391D0 (en) Compositions
GB0119469D0 (en) Novel compositions
GB0114314D0 (en) Novel compositions
GB0107904D0 (en) Novel compositions
GB0101334D0 (en) Novel compounds
GB0102577D0 (en) Novel Compounds
GB0100179D0 (en) Novel compounds
GB0101437D0 (en) Novel Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)